Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 30, 2012

View Archived Issues

Evotec and Probiodrug enter development collaboration for novel enzyme target

Kythera's ATX-101 is safe in interim study results

Proof-of-concept results reported for BAY-94-8862

Starpharma reports data from two phase III VivaGel studies

PAX2 identified in CNS hemangioblastomas

Shionogi & Co. presents new NPY5 receptor antagonists

RVX-297 reduces clinical signs of disease in a rat model of rheumatoid arthritis

First-in-human study of AT-406 described

Novel PDE10 inhibitors disclosed by Mochida Pharmaceutical

Exelixis prepares new iPFK2 inhibitors for cancer

Curis licenses GDC-0917 from Genentech

Shionogi & Co. presents new BACE1 inhibitors

Merck & Co. updates on ridaforolimus MAA

Japan Tobacco designs novel RORgamma antagonists

Protalex treats first patient phase Ib PRTX-100 trial

MM-938 significantly reduces tumor growth rates in glioblastoma mouse models

Novel protein kinase inhibitors patented by Abbott Laboratories

Nordic Pharma gains marketing rights for Veregen in certain countries

Preclinical and phase I data presented for AP-26113

Bayer and Leiden University to coordinate drug discovery consortium

Tekmira acquires license to RNAi technology

Phase II trial of pancreas cancer vaccines completes enrollment

Immunovative Therapies receives clearance for phase II/III trial in Thailand

Novel mouse model of NSF developed at Thomas Jefferson University

FDA approves Cometriq, EMA accepts MAA

Enrollment complete in pivotal U.S. phase III trial of NX-1207

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...